Locations:
Search IconSearch

Multiple Sclerosis

21-NEU-2245408_mri-in-MS_650x450

How Well Do Current MRI Modalities Measure Cortical Lesion Load in Multiple Sclerosis?

Shortcomings in specificity show influence of cortical changes beyond demyelination

thalamic lesions in multiple sclerosis

Deep Gray Matter Injury in Multiple Sclerosis: What We Know, Why It Matters

A new NAIMS consensus statement summarizes evidence, guides MRI investigation

21-NEU-2079842_COVID-19-in-MS-patients_650x450
March 29, 2021/COVID-19

Registry Study Pinpoints Risk Factors for Worse COVID-19 Outcomes in Patients With MS

Ambulation disability carries greatest risk, most disease-modifying therapies aren’t implicated

brain MRI hereditary spastic paraplegia
March 9, 2021/Genomic Medicine

Learning from Multiple Sclerosis Misdiagnosis: Insights Into Genetic Leukodystrophies

Clinical cohort study helps define red flags for these rare MS mimics

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

21-NEU-2050870_woman-in-wheelchair_650x450

How Do Patients With Multiple Sclerosis Perceive the U.S. Drug Approval Process?

Survey suggests need for education about FDA’s mission, trustworthiness

21-NEU-2046760_CQD_650x450_200158799_with mask

In Patients With NMOSD, Early Age at Onset Is Associated With Severity of Visual Loss

Large cohort study supports early consideration of aggressive therapy

Bethoux, MD

Cannabis Extract Improves Spasticity Without Increasing Weakness in Patients With MS

Cannabinoid oromucosal spray is poised for FDA submission in 2021

BackPage 5 of 5Next

Advertisement

Ad